SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
pills Medicine tablet in blister pack on a yellow background
Manufacturing
Sertraline manufacturer recalls antidepressant batch after UK packaging mix-up
A subsidiary of Indian drugmaker Hetero Group mistakenly packaged two types of antidepressants in packs of sertraline, potentially posing risks to patients.
May 5, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Colorful light bulb exploding glass flying everywhere black background
Earnings
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in
As Q1 earnings arrive, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least partly on novel assets for obesity.
May 5, 2026
 · 
5 min read
 · 
Heather McKenzie
Illustration depicting layoffs with index finger overturning row of businessmen standing on big hands
Layoffs
Passage cuts 75% of workforce after FDA trial design request
Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include frontotemporal dementia, is exploring strategic alternatives in addition to cutting staff.
May 4, 2026
 · 
1 min read
 · 
Angela Gabriel
Opinion
Gene therapy’s evidence problem—lessons from recent FDA decisions
Comprehending the spate of recent rejections in the cell and gene therapy space may require looking no further than early-stage clinical trials of candidates from REGENXBIO, Excision BioTherapeutics and Intellia Therapeutics.
May 4, 2026
 · 
6 min read
 · 
Jenna DiRito
pharmaceutical industry, medicine pills are filling in the bottle on production line machine conveyor at the medical factory. selective focus.
Manufacturing
PCI adds US sterile fill/finish capabilities through $1B global expansion drive
Amid disruption to the outsourced fill/finish market, PCI is investing $100 million to more than double the capacity to fill ready-to-use prefilled syringes and cartridges at its San Diego campus.
May 4, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A flower in the middle of the desert
Adcomms
First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial
The advisory committee meeting—the FDA’s first drug-related adcomm in nine months—could have been a “more conceptual discussion” about the design of AstraZeneca’s Phase 3 trial of camizestrant in HER2-negative advanced breast cancer, former cancer regulator Harpreet Singh told BioSpace.
May 4, 2026
 · 
9 min read
 · 
Tristan Manalac
Illustration showing three businesspeople hanging on the edge of a cliff
Lung cancer
Summit shares descend as PD-1/VEGF asset misses early survival mark
Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders.
May 4, 2026
 · 
2 min read
 · 
Tristan Manalac
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Approvals
FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.
May 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Woman taking retro photos. Digital collage with female hands holding vintage camera. Pop art design. Concept of social media
Mergers & acquisitions
UCB captures Candid in $2.2B autoimmune deal as pharma’s M&A train chugs along
Candid Therapeutics follows closely behind Neurona Therapeutics, which UCB acquired in mid-April in a potential $1.15 billion deal.
May 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS